

Stuart A Nicklin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7033095/stuart-a-nicklin-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

3,732
citations

28
h-index

60
g-index

60
ext. papers

4,354
ext. citations

8.1
avg, IF

4.9
L-index

#	Paper	IF	Citations
55	Agonist-induced phosphorylation of orthologues of the orphan receptor GPR35 functions as an activation sensor.. <i>Journal of Biological Chemistry</i> , 2022 , 101655	5.4	2
54	Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. <i>Journal of Molecular Medicine</i> , 2022 , 100, 875-901	5.5	1
53	Preclinical models of myocardial infarction: from mechanism to translation. <i>British Journal of Pharmacology</i> , 2021 ,	8.6	1
52	In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications. <i>Viruses</i> , 2021 , 13,	6.2	3
51	RUNX1: an emerging therapeutic target for cardiovascular disease. <i>Cardiovascular Research</i> , 2020 , 116, 1410-1423	9.9	15
50	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. <i>Cardiovascular Research</i> , 2020 , 116, 1666-1687	9.9	714
49	Regulation of connexin 43 by interleukin 1 β in adult rat cardiac fibroblasts and effects in an adult rat cardiac myocyte: fibroblast co-culture model. <i>Heliyon</i> , 2020 , 6, e03031	3.6	5
48	Signalling pathways linking cysteine cathepsins to adverse cardiac remodelling. <i>Cellular Signalling</i> , 2020 , 76, 109770	4.9	1
47	The role of extracellular vesicles in neointima formation post vascular injury. <i>Cellular Signalling</i> , 2020 , 76, 109783	4.9	3
46	Extracellular vesicle signalling in atherosclerosis. <i>Cellular Signalling</i> , 2020 , 75, 109751	4.9	11
45	The counter regulatory axis of the renin angiotensin system in the brain and ischaemic stroke: Insight from preclinical stroke studies and therapeutic potential. <i>Cellular Signalling</i> , 2020 , 76, 109809	4.9	5
44	Assessing the effects of Ang-(1-7) therapy following transient middle cerebral artery occlusion. <i>Scientific Reports</i> , 2019 , 9, 3154	4.9	10
43	Human Adenovirus Serotype 5 Is Sensitive to IgM-Independent Neutralization In Vitro and In Vivo. <i>Viruses</i> , 2019 , 11,	6.2	5
42	Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment. <i>JCI Insight</i> , 2019 , 4,	9.9	21
41	Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction. <i>Circulation</i> , 2018 , 137, 57-70	16.7	38
40	Utilizing proteomics to understand and define hypertension: where are we and where do we go?. <i>Expert Review of Proteomics</i> , 2018 , 15, 581-592	4.2	8
39	The Orphan Receptor GPR35 Contributes to Angiotensin II-Induced Hypertension and Cardiac Dysfunction in Mice. <i>American Journal of Hypertension</i> , 2018 , 31, 1049-1058	2.3	11

38	Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction in the Presence of Mouse Serum. <i>Journal of Virology</i> , 2017 , 91,	6.6	10
37	The relevance of coagulation factor X protection of adenoviruses in human sera. <i>Gene Therapy</i> , 2016 , 23, 592-6	4	14
36	Retargeting FX-binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. <i>Journal of General Virology</i> , 2016 , 97, 1911-1916	4.9	6
35	Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2652-2666	15.1	24
34	G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. <i>Frontiers in Pharmacology</i> , 2015 , 6, 41	5.6	47
33	Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2. <i>Circulation Research</i> , 2015 , 117, 707-19	15.7	75
32	Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. <i>PLoS Pathogens</i> , 2015 , 11, e1004673	7.6	35
31	Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. <i>Human Gene Therapy</i> , 2015 , 26, 312-9	4.8	20
30	G-Protein-Coupled Receptor 35 Mediates Human Saphenous Vein Vascular Smooth Muscle Cell Migration and Endothelial Cell Proliferation. <i>Journal of Vascular Research</i> , 2015 , 52, 383-95	1.9	15
29	Electrical consequences of cardiac myocyte: fibroblast coupling. <i>Biochemical Society Transactions</i> , 2015 , 43, 513-8	5.1	20
28	The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery. <i>Expert Opinion on Drug Delivery</i> , 2014 , 11, 1795-813	8	17
27	Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. <i>Clinical Science</i> , 2014 , 126, 815-27	6.5	89
26	The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. <i>Molecular Pharmacology</i> , 2014 , 85, 91-104	4.3	37
25	Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012 , 343, 683-95	4.7	32
24	Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. <i>Hypertension</i> , 2012 , 59, 300-7	8.5	77
23	Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor. <i>PLoS ONE</i> , 2012 , 7, e45564	3.7	46
22	Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. <i>Journal of Physiology</i> , 2011 , 589, 939-51	3.9	69
21	Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. <i>PLoS Pathogens</i> , 2010 , 6, e1001142	7.6	61

20	Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. <i>PLoS Genetics</i> , 2010 , 6, e1001177	6	255
19	Adenoviral Vectors 2010 , 21-36		
18	Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. <i>Blood</i> , 2010 , 116, 2656-64	2.2	88
17	Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. <i>Journal of Virology</i> , 2009 , 83, 479-83	6.6	56
16	Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. <i>Molecular Therapy</i> , 2009 , 17, 1683-91	11.7	35
15	Onset of experimental severe cardiac fibrosis is mediated by overexpression of Angiotensin-converting enzyme 2. <i>Hypertension</i> , 2009 , 53, 694-700	8.5	36
14	Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. <i>Blood</i> , 2009 , 114, 965-71	2.2	142
13	Adenovirus serotype 5 hexon mediates liver gene transfer. <i>Cell</i> , 2008 , 132, 397-409	56.2	495
12	Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. <i>Current Opinion in Molecular Therapeutics</i> , 2008 , 10, 439-48		25
11	Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. <i>Journal of Virology</i> , 2007 , 81, 9568-71	6.6	66
10	Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. <i>Blood</i> , 2006 , 108, 2554-61	2.2	223
9	The influence of adenovirus fiber structure and function on vector development for gene therapy. <i>Molecular Therapy</i> , 2005 , 12, 384-93	11.7	138
8	In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. <i>Journal of Gene Medicine</i> , 2004 , 6, 300-8	3.5	44
7	Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. <i>Human Gene Therapy</i> , 2004 , 15, 1054-64	4.8	48
6	Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. <i>Cancer Letters</i> , 2003 , 201, 165-73	9.9	28
5	Development of targeted viral vectors for cardiovascular gene therapy. <i>Genetic Engineering</i> , 2003 , 25, 15-49		2
4	Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. <i>Nature Biotechnology</i> , 2001 , 19, 838-42	44.5	204
3	Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. <i>Molecular Therapy</i> , 2001 , 4, 534-42	11.7	121

- | | | | |
|---|---|------|-----|
| 2 | Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. <i>Circulation</i> , 2000 , 102, 231-7 | 16.7 | 139 |
| 1 | Simple methods for preparing recombinant adenoviruses for high-efficiency transduction of vascular cells. <i>Methods in Molecular Medicine</i> , 1999 , 30, 271-83 | | 24 |